BridgeBio Oncology Therapeutics, Inc.
BBOT
$9.05
$0.171.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -134.04M | -114.93M | -87.50M | -80.89M | -74.28M |
| Total Depreciation and Amortization | 610.00K | 468.00K | 339.00K | 210.00K | 208.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.11M | 10.45M | 2.02M | 2.82M | 3.45M |
| Change in Net Operating Assets | 6.43M | 17.32M | 4.24M | 12.09M | 15.59M |
| Cash from Operations | -113.89M | -86.70M | -80.90M | -65.76M | -55.03M |
| Capital Expenditure | -606.00K | -543.00K | -414.00K | -197.00K | -49.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 73.93M | 91.66M | 54.00M | -107.36M | -120.48M |
| Cash from Investing | 73.33M | 91.12M | 53.59M | -107.55M | -120.53M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 373.50M | 373.51M | 52.00K | 382.00K | 1.11M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 22.22M | 22.22M | 22.22M | 199.26M | 205.18M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -12.32M | -11.69M | -3.67M | -404.00K | -- |
| Cash from Financing | 383.40M | 384.04M | 18.60M | 199.24M | 206.29M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 342.84M | 388.46M | -8.71M | 25.92M | 30.73M |